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Background. Human immunodeﬁciency virus type 1 (HIV-1) transmitted drug resistance (TDR) can compromise
antiretroviral therapy (ART) and thus represents an important public health concern. Typically, sources of TDR remain
unknown, but they can be characterized with molecular epidemiologic approaches. We used the highly representative
Swiss HIV Cohort Study (SHCS) and linked drug resistance database (SHCS-DRDB) to analyze sources of TDR.
Methods. ART-naive men who have sex with men with infection date estimates between 1996 and 2009 were
chosen for surveillance of TDR in HIV-1 subtype B (N = 1674), as the SHCS-DRDB contains pre-ART genotypic re-
sistance tests for >69% of this surveillance population. A phylogeny was inferred using pol sequences from surveillance
patients and all subtype B sequences from the SHCS-DRDB (6934 additional patients). Potential sources of TDR were
identiﬁed based on phylogenetic clustering, shared resistance mutations, genetic distance, and estimated infection
dates.
Results. One hundred forty of 1674 (8.4%) surveillance patients carried virus with TDR; 86 of 140 (61.4%) were
assigned to clusters. Potential sources of TDR were found for 50 of 86 (58.1%) of these patients. ART-naive patients
constitute 56 of 66 (84.8%) potential sources and were signiﬁcantly overrepresented among sources (odds ratio, 6.43
[95% conﬁdence interval, 3.22–12.82]; P < .001). Particularly large transmission clusters were observed for the L90M
mutation, and the spread of L90M continued even after the near cessation of antiretroviral use selecting for that muta-
tion. Three clusters showed evidence of reversion of K103N or T215Y/F.
Conclusions. Many individuals harboring viral TDR belonged to transmission clusters with other Swiss patients,
indicating substantial domestic transmission of TDR in Switzerland. Most TDR in clusters could be linked to sources,
indicating good surveillance of TDR in the SHCS-DRDB. Most TDR sources were ART naive. This, and the presence
of long TDR transmission chains, suggests that resistance mutations are frequently transmitted among untreated indi-
viduals, highlighting the importance of early diagnosis and treatment.
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Antiretroviral treatment (ART) has drastically reduced human
immunodeﬁciency virus (HIV)–related morbidity and mortali-
ty since the late 1980s [1–3]. However, ART has been shown to
be less effective against drug-resistant HIV type 1 (HIV-1) [4],
which may take longer to be suppressed and may cause virolog-
ical failure earlier [5]. Resistance is seen in individuals undergo-
ing ART (acquired drug resistance), and in those who have
never undergone ART (transmitted drug resistance [TDR]) [6, 7].
Estimates of the prevalence of drug resistance among new in-
fections (TDR) vary worldwide between 4% and 22% [8–12].
Thus, reducing TDR is an important public health goal.
Several studies have documented stable or decreasing TDR
rates in Europe and North America in recent years [10, 12–15]. In
addition to such direct quantiﬁcation of TDR cases, molecular epi-
demiology offers a unique tool for characterizing the sources of
transmitted drug resistance in HIV-1 [14, 16]. Phylogenetics
reveals evolutionary relationships between genetic sequences, and
is an established method for characterizing transmission of rapidly
evolving pathogens [17–21]. Usually, sources of TDR remain
unknown, but if 2 patients cluster on a phylogeny, one is a poten-
tial source of the other’s infection and TDR. Many previous phy-
logenetic analyses of HIV-1 TDR were limited by the number of
patients included, the representativeness of the study population,
and/or limited information on infection dates or patient ART his-
tories. Thus, a data set with high coverage of a (sub-)epidemic pro-
vides a unique opportunity to investigate the sources of TDR.
The Swiss HIV Cohort Study (SHCS) is a clinic-based pro-
spective cohort study continuously enrolling patients from all
of Switzerland. The linked drug resistance database (SHCS-
DRDB) contains all genotypic resistance tests (GRTs) conduct-
ed in Switzerland, providing a uniquely representative source of
genetic, epidemiologic, demographic, and clinical data, which
we use here to characterize the sources of TDR with a molecu-
lar epidemiologic approach.
METHODS
Subject/Sequence Selection
The SHCS has >17 900 patients followed semiannually (www.
shcs.ch) [22]. Informed consent was obtained from all patients
and the study was approved by the ethics committees of the
participating institutions. The SHCS-DRDB [23] contains all
GRTs from the 4 laboratories in Switzerland that conduct HIV
drug resistance testing. Sequences include the full protease and
at least codons 28–225 of the reverse transcriptase. Sequences
were obtained from routine clinical testing (60%) and system-
atic retrospective sequencing of stored plasma samples (40%).
The SHCS-DRDB contains >19 000 partial pol gene sequences
from >10 000 patients. It is unique in achieving good coverage
of the population of HIV-infected patients for an entire
country: Approximately 54% of all HIV cases ever diagnosed in
Switzerland and 75% of antiretroviral-treated patients are in the
SHCS [22]. Viral nucleotide sequences are available for 62.5%
of patients in the SHCS [22, 24]. Infection dates were imputed
from CD4 cell counts by the back-calculation method pub-
lished in [25].
To analyze the incidence and phylogenetic linkage of TDR in a
highly representative population, we use ART-naive men who
have sex with men (MSM) infected between 1996 and 2009 as a
surveillance population (see Results and Figure 1). We focused on
this group for the following reasons: First, subtype B is the main
subtype transmitted in Switzerland [26]. Second, there is substan-
tial ongoing transmission in Switzerland among MSM [27].
Third, stored plasma samples for systematic retrospective se-
quencing were available starting from 1996. Finally, there was
typically a delay of several years (median, 4.17 years [interquar-
tile range, 2.98–5.82 years]) between infection and enrollment
in the cohort [25]. Along with 1674 surveillance patients, all
6934 remaining SHCS-DRDB patients with subtype B HIV
were included as a background for the phylogenetic tree and as
additional potential sources of TDR.
To assess representativeness of the surveillance population,
we used data from the Swiss Federal Ofﬁce of Public Health
(SFOPH) on the yearly HIV-1 diagnoses in Switzerland, by
transmission group. As the SFOPH data do not contain
subtype information or infection dates, we used diagnosis date
as a proxy for infection date and pooled all subtypes for our
representativeness calculations. We calculated the representa-
tiveness of the SHCS-DRDB for given ranges of diagnosis dates
by comparing the number of patients with available pre-ART
GRTs in the SHCS-DRDB to the number of newly diagnosed
HIV cases in Switzerland, according to the SFOPH (http://
www.bag.admin.ch/hiv_aids/05464/12908/12909/12913/index.
html?lang=de).
Patients carrying TDR (“recipients” of TDR) were identiﬁed
from the surveillance population. However, potential transmit-
ters of TDR are not restricted to this group; all other patients
(drug naive, treated, or treatment failing) with available HIV-1
subtype B pol gene sequences were included as a background
for tree building (“background population”), and both popula-
tions were considered possible transmitters of drug-resistant
HIV (potential “sources” of TDR). In total, 15 681 HIV-1 pol
gene sequences from 8608 subtype B patients from the SHCS
were analyzed (Figure 1). Because sequences for several time
points could be included for the same patient, only mutations
found while a patient was ART naive were considered TDR.
However, mutations from any time were considered when de-
termining if a patient was a source of TDR. For deﬁnitions of
all terms used for groups of patients, see Table 1.
Drug resistance mutations were deﬁned as amino acid substi-
tutions on the World Health Organization HIV Drug Resis-
tance Surveillance list [28].
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Phylogenetic Analysis
A phylogeny was inferred from 15 681 pol gene nucleotide se-
quences. Nucleotide positions where resistance mutations are
documented [28] were excluded for tree inference. The tree was
created using the GTR model in the software FastTree2 [29, 30].
Support values for the branching pattern were calculated from
100 bootstrap replicates.
Monophyletic groups with bootstrap support ≥70% (“trans-
mission clusters”) were investigated for TDR recipients and
sources. Two very large clusters containing sequences from 210
and 43 patients were excluded and smaller clusters nested
within them analyzed instead. In all other cases, clusters nested
within larger clusters were excluded. Additionally, a sensitivity
analysis was conducted with a bootstrap threshold of ≥98%.
Potential sources of TDR were identiﬁed from those patients
who clustered with and shared ≥1 drug resistance mutations
with a recipient of TDR and satisﬁed 2 criteria: The estimated
infection dates with 95% conﬁdence intervals (CIs) did not
exclude that the source was infected before the recipient, and
the genetic distance of the source viral sequence from that of
the corresponding recipient was <1.5% (Table 1).
Primary/Recent Infections
We calculated the fraction of primary/recent infections among
sources of TDR. Primary/recent infections were deﬁned by
diagnosis during clinically deﬁned acute HIV infection (http://
www.shcs.ch/56-deﬁnitions#2.1) or during recent infection
deﬁned by seroconversion (<1 year between last negative and
ﬁrst positive HIV test), or by an ambiguous nucleotide count of
<0.5% in a baseline, ART-naive GRT [31] (Table 1).
Statistical analyses were done using R version 2.15.1 and
Stata/SE12.1. Comparisons between groups were performed
with Fisher test for count data, or Welch t test for means. For
surveillance patients with and without TDR, we assessed the
role of infection date, clustering status, age at time of infection,
and whether a patient was diagnosed in primary infection,
using univariable and multivariable logistic regression. For po-
tential sources vs nonsources, we additionally analyzed the role
of sex, transmission group, and TDR. The multivariable logistic
regressions controlled for the potential confounders listed
above (see also Tables 2 and 3).
RESULTS
Representativeness
We considered the phylogenetic linkage of transmitted drug re-
sistance mutations in subtype B HIV-1 in a surveillance popu-
lation of therapy-naive MSM with estimated infection dates
between 1996 and 2009 (see Methods) and calculated the repre-
sentativeness for this group using data from the SFOPH.
Figure 1. A, Sequence selection for inclusion in the analysis, and deﬁnition of the surveillance (red box) and background populations (gray boxes).
B, Possible transmission of drug resistance mutations. Transmitted drug resistance can be transmitted to the surveillance patients (red box) from either the
background population (gray box) or another member of the surveillance population. Abbreviations: ART, antiretroviral therapy; GRT, genotypic resistance
test; HIV, human immunodeﬁciency virus; MSM, men who have sex with men; SHCS-DRDB, Swiss HIV Cohort Study drug resistance database.
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Overall, the SHCS contains at least 53.6% of all patients ever
diagnosed in Switzerland, according to data from the SFOPH.
The SHCS-DRDB contains pre-ART GRTs for 22.1% of pa-
tients (see Methods). Overall, a higher fraction of patients diag-
nosed from 1996 to 2009 had pre-ART sequences in the DRDB
than did all patients (50.8% vs 22.1%). Combining this with the
restriction of transmission group to MSM, we found that 69.3%
of MSM diagnosed from 1996 to 2009 had pre-ART sequences
in the SHCS-DRDB. Although we selected surveillance patients
using estimated infection dates and not diagnosis dates, the
above percentages support our choice to limit the transmission
group and infection dates of the surveillance population.
Clustering
Of the analyzed patients, 3225 of 8608 (38.0%) belonged to
transmission clusters with bootstrap support ≥70%, including
1119 of 1674 (66.8%) surveillance patients. Thus, surveillance
patients had a much higher rate of clustering than nonsurveil-
lance patients (odds ratio [OR], 3.36 [95% CI, 3.0–3.77];
P < .001). Of surveillance patients with TDR, 86 of 140 (61.4%)
belonged to transmission clusters. The presence of TDR did
not impact clustering (OR, 0.77 [95% CI, .53–1.12]; P = .16).
Characteristics of Transmitted Resistance
Of 1674 surveillance patients, 140 (8.4%) carried virus with
TDR [28]. Notably, patients with TDR were more often diag-
nosed during primary infection (OR, 1.51 [95% CI, 1.06–2.14];
P = .02). See Table 2 for further characteristics of surveillance
patients with and without TDR.
Of the 140 surveillance patients carrying TDR, 114 (81.4%)
carried virus with mutations against 1 drug class, 16 (11.4%)
against 2 classes, and 10 (7.1%) against 3 classes. Ninety-three
(66.4%) of surveillance TDR sequences carried resistance
against nonnucleoside reverse transcriptase inhibitors, 45
(32.1%) against protease inhibitors, and 38 (27.1%) against
nonnucleoside reverse transcriptase inhibitors. Moreover, 61
carried >1 mutation (range, 1–9). The most commonly mutated
position in surveillance-patient viruses was codon 215 in the
RT, similar to [14]. A total of 53 RT mutations at codon 215
were found (T215Y/S/C/D/E/L/F). In the surveillance popula-
tion, T215F/Y constitute only 10 of 53 (18.9%) resistance muta-
tions at position 215, whereas they constitute 1124 of 1234
(91.1%) resistance mutations for ART-experienced patients.
See the Supplementary Data for complete lists of transmitted/
acquired resistance mutations.
Evidence of Resistance Transmission
We could link most surveillance population TDR in clusters to
a potential source of the drug resistance mutation(s). Speciﬁ-
cally, we found that of the surveillance patients who had TDR
and belonged to transmission clusters, 50 of 86 (58.1%) clus-
tered with at least 1 potential source. For 35 of 50 (70%), >1
possible source was identiﬁed (range, 1–7). Sources were often
associated with multiple surveillance patients.
We found that surveillance patients were more likely to carry
resistant virus if they belonged to a cluster containing resistant
virus in other patients. For surveillance sequences with TDR in
clusters, there was at least 1 other patient carrying resistant
Table 1. Deﬁnitions of Terms Used
Term Definition
Surveillance population MSM, subtype B patients with at least 1
genetic resistance test prior to
beginning ART, and whowere infected
between 1996 and 2009 (based on a
back-calculation method from Taffé
et al [25])
Background population All subtype B patients in the analysis who
were not in the surveillance population
Recipient (of TDR) A surveillance patient with a TDR
mutation
Potential source (of
TDR)
Any patient (from surveillance or
background population) who shares a
resistance mutation with a patient with
TDR in a well-supported cluster, and
meets the following criteria:
• Genetic distance to the
corresponding TDR patient is
<1.5%
• Estimated infection dates with 95%
confidence intervals do not exclude
that the potential source was
infected before the corresponding
recipient of TDR (estimated date for
source is earlier, or confidence
intervals overlap)
Treatment-naive
potential source
A potential source of TDR for whom a
genetic test indicates that the relevant
mutation was present before the
patient had begun ART
Treatment-experienced
potential source
A potential source of TDR for whom the
first available genetic test with the
relevant mutation present was
conducted after the patient had begun
ART
Non–source patient with
the potential to
transmit resistance
A patient with a resistance mutation,
from the background or surveillance
population, who clusters with a
surveillance patient, but is not a
potential source
Patient with primary or
recent infection
A patient with a primary/recent infection
by 1 of 3 criteria:
• Clinical identification of acute HIV
infection
• <1 year between the last
documented negative and first
documented positive HIV test
• <0.5% ambiguous nucleotides in a
baseline, ART-naive genetic sample
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency
virus; MSM, men who have sex with men; TDR, transmitted drug resistance.
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virus in the same cluster in 74 of 86 (86%) cases. For the sur-
veillance population patients without TDR mutations, only 246
of 1033 (23.8%) clustered with another patient carrying resis-
tant virus. The presence of a viral resistance mutation is thus a
very strong predictor of other patients with resistance muta-
tions in the same transmission cluster (OR, 19.7 [95% CI, 10.4–
40.4]; P < .001).
Sources of Transmitted Resistance
Fifty-six of 66 (84.8%) potential source patients were ART
naive when the relevant mutation was ﬁrst observed. We com-
pared this with the fraction of ART-naive patients among non-
source patients with the potential to transmit resistance. These
nonsource patients were deﬁned as patients with HIV-1 resis-
tance mutations who belonged to a cluster with a surveillance
patient but were not sources of TDR (Table 1). Treatment-
naive patients were signiﬁcantly overrepresented among poten-
tial sources of TDR compared to nonsources (OR, 6.43 [95%
CI, 3.22–12.82]; P < .001).This signiﬁcance remains when con-
trolling for potential confounders (Table 3). Of 50 surveillance
patients with viral TDR and a potential source, 43 (86%) had at
least 1 ART-naive patient among their potential sources. By
contrast, only 17 of 50 (34%) were in clusters with treated po-
tential sources. Thus, most resistance mutations were transmit-
ted to >1 naive individual, and a single initial transmission event
from a treated patient may lead to several new infections with
drug-resistant HIV. Sources were infected later than nonsources,
likely because the surveillance population was characterized by
more recent infection dates than the background population
(see Methods). As the sources of TDR will be more similar to re-
cipients (which stem by deﬁnition from the surveillance popula-
tion), this will result in sources having more recent infection
dates than nonsources. Further comparisons are shown in
Table 3.
Potential Role of Recent Infections
Given the possibility of reversion of drug resistance in untreat-
ed individuals, transmission of drug-resistant virus may be
more likely if the source has been recently infected. We thus
considered the fraction of primary and recent infections among
the sources of TDR (see Methods). Thirty-four of 66 (51.5%) po-
tential sources of TDR were individuals diagnosed in primary/
recent infection, compared with only 57 of 187 (30.5%) of non-
source patients who carried resistance mutations and clustered
with surveillance patients. The difference was signiﬁcant (OR,
2.42 [95% CI, 1.36–4.3]; P≤ .001), but when controlling for esti-
mated date of infection, signiﬁcance was lost (P = .98).
Notable Individual Clusters
Two striking examples of long TDR transmission chains are
shown in Figure 2. In Figure 2A, 2 treated patients and 7 drug-
naive patients carry virus with L90M in the protease gene. In
Figure 2B, 11 drug-naive patients carry virus with L90M, but
no treated patients are present. These transmission chains indi-
cate that either a treated patient transmitted resistant virus to
several uninfected people, or that patients infected with
Table 2. Characteristics of Surveillance Patients With and Without Transmitted Drug Resistance
With TDR, Without TDR,
Univariable Multivariable
Characteristic No. (%) No. (%) Total, No. OR (95% CI) P Value OR (95% CI) P Value
Age at time of infection .09 .07
≤29 30 (21) 287 (19) 317 1 (Reference) 1 (Reference)
30–39 64 (46) 614 (40) 678 1.00 (.63–1.57) 1.01 (.64–1.61)
40–49 39 (28) 439 (29) 478 0.85 (.52–1.4) 0.87 (.53–1.44)
≥50 7 (5) 194 (13) 201 0.35 (.15–.8) 0.35 (.15–.83)
Patient is in a cluster .16 .08
No 54 (39) 501 (33) 555 1 (Reference) 1 (Reference)
Yes 86 (61) 1033 (67) 1119 0.77 (.54–1.1) 0.73 (.51–1.04)
Year of infection .62 .65
1996–2000 39 (28) 463 (30) 502 1 (Reference) 1 (Reference)
2001–2003 35 (25) 352 (23) 387 1.18 (.73–1.9) 1.17 (.72–1.89)
2004–2006 37 (26) 455 (30) 492 0.97 (.6–1.54) 0.97 (.60–1.55)
2007–2009 29 (21) 264 (17) 293 1.3 (.79–2.16) 1.24 (.74–2.08)
Primary infection at registration .02 .029
No 59 (42) 803 (52) 862 1 (Reference) 1 (Reference)
Yes 81 (58) 731 (48) 812 1.51 (1.06–2.14) 1.46 (1.02–2.09)
The odds ratios in the multivariable model are adjusted for all variables listed in the table.
Abbreviations: CI, confidence interval; OR, odds ratio; TDR, transmitted drug resistance.
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resistant HIV transmitted the resistant virus further. Thus, for
the L90M mutation, reversion does not necessarily occur
quickly or completely in absence of ART.
The 90M mutation confers resistance to nelﬁnavir and saqui-
navir [32], protease inhibitors whose use has decreased dramat-
ically over time. Speciﬁcally, saquinavir and nelﬁnavir were
used in ART for 30% and 10% of patients in the SHCS in the
late 1990s, but for <5% of patients by 2005 and 2000, respec-
tively. However, no similar decrease was seen in the incidence of
transmitted 90M mutations (Figure 3). This strongly suggests
continuing transmission among naive patients, independent of
ART usage, as does our ﬁnding of large 90M transmission chains
dominated by ART-naive transmitters.
One cluster contained signatures of reversion of drug resis-
tance mutations. Figure 2C shows a cluster with 5 drug-naive se-
quences sharing at least 1 mutation. In addition, 1 viral sequence
(labeled with **) harbors the 215F mutation. Interestingly, the
215F mutation is not present in 2 sequences from earlier infec-
tions in the cluster (green triangles). The infection dates and
close phylogenetic relationships imply that this patient likely
acquired his HIV infection from one of the earlier infected pa-
tients in this cluster; however, we did not observe the 215F mu-
tation in virus from either of the earlier infected patients.
Notably, the earlier infected patients (green triangles) had
GRTs from a later date than the patient marked by **, so rever-
sion of the 215F mutation could have occurred between trans-
mission and sampling of the source patient’s virus. Viruses
from the other 4 patients in this cluster have the rare, but not
resistance conferring, 215L mutation. 215L occurs only in 62 of
15 681 (0.4%) subtype B sequences in the SHCS-DRDB.
Sensitivity Analysis
A sensitivity analysis explored how the results changed depend-
ing on the criteria deﬁning potential TDR sources (Figure 4).
Table 3. Description of Sources and Nonsources Among Patients With Resistance Mutations Who Cluster With Surveillance Patients
Univariable Multivariable
Sources,
No. (%)
Nonsources,
No. (%)
Total
No. OR (95% CI) P Value OR (95% CI) P Value
Transmission group .69 .34
MSM 56 (85) 155 (83) 211 1.00 (Reference) 1 (Reference)
Heterosexual 6 (9) 19 (10) 25 0.87 (.33–2.30) 1.15 (.33–4.03)
IDU 1 (2) 7 (4) 8 0.40 (.05–3.29) 0.75 (.07–8.40)
Other/unknown 3 (5) 5 (3) 8 1.66 (.38–7.18) 6.61 (.94–46.30)
Sex .19 .14
Male 65 (98) 177 (95) 242 1 (Reference) 1 (Reference)
Female 1 (2) 9 (5) 10 0.30 (.04–2.44) 0.18 (.02–2.12)
Age at time of infection .98 .73
≤29 28 (42) 79 (42) 107 1 (Reference) 1 (Reference)
30–39 26 (39) 73 (39) 99 1.00 (.54–1.87) 0.87 (.42–1.8)
40–49 8 (12) 25 (13) 33 0.90 (.37–2.23) 0.56 (.2–1.6)
≥50 4 (6) 9 (5) 13 1.25 (.36–4.40) 1.09 (.22–5.49)
Year of infection <.001 <.001
1985–1994 3 (5) 24 (13) 27 1 (Reference) 1 (Reference)
1995–1999 7 (11) 90 (48) 97 0.62 (.15–2.59) 0.37 (.08–1.76)
2000–2004 27 (41) 40 (22) 67 5.40 (1.48–19.73) 2.36 (.53–10.54)
2005–2009 22 (33) 28 (15) 50 6.29 (1.67–23.62) 2.81 (.59–13.37)
2010–2013 7 (11) 4 (2) 11 14.00 (2.51–77.99) 4.89 (.64–37.22)
Primary infection at registration .003 .98
No 32 (48) 130 (70) 162 1 (Reference) 1 (Reference)
Yes 34 (52) 57 (30) 91 2.42 (1.36–4.30) 1.01 (.49–2.10)
ART-naive at when mutation
was observed
<.001 .011
No 12 (18) 110 (59) 122 1 (Reference) 1 (Reference)
Yes 54 (82) 77 (41) 131 6.43 (3.22–12.82) 3.20 (1.27–8.05)
The odds ratios in the multivariable model are adjusted for all variables listed in the table.
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; IDU, injection drug user; MSM, men who have sex with men; OR, odds ratio.
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The number of source-recipient pairs in clusters decreases with
stricter bootstrap or distance criteria. The fraction of naive
sources, however, did not change signiﬁcantly with the boot-
strap or distance criteria (results not shown).
DISCUSSION
Here we investigated HIV-1 TDR in the SHCS-DRDB, which is
representative for the HIV-infected population in Switzerland
and contains exact treatment histories and estimates of infec-
tion dates. The high proportion (86/140 [61.4%]) of TDR-
carrying individuals who belonged to Swiss transmission clusters
indicates a major role for domestic transmission in the acquisi-
tion of TDR in our study population. Of TDR-carrying pa-
tients in domestic clusters, we linked many (50/86 [58.1%]) to
sources, underlining the high-quality surveillance of domestic
TDR in the SHCS-DRDB. We also found that drug-resistant
HIV is transmitted between MSM and heterosexuals or injec-
tion drug users (Supplementary Data) [27].
We tested whether primary/recent infections were particu-
larly important for the transmission of drug resistance. The fre-
quency of primary infections in transmission clusters has been
used to assess the importance of early infections in HIV
transmission [14, 21, 33]. As diagnosis and treatment can lead
to decreased risk behavior and lowered viral loads, transmission
is less likely to occur after diagnosis [34]. Therefore, the pro-
portion of infections diagnosed during early infection is a
proxy for the amount of HIV transmission that occurred
during early infection. We found a signiﬁcant increase in the
fraction of individuals diagnosed in primary infection among
potential sources of TDR. However, when controlling for year
of infection, the effect became nonsigniﬁcant. More generally,
the increasing fraction of patients diagnosed during primary in-
fection in recent years may confound assessments of the impor-
tance of primary infection.
We found some evidence of reversion. Figure 3C showed
possible reversion of the 215F mutation, as potential sources in
this cluster carried mutation 215L, an atypical amino acid that
has been shown to emerge after 215F [35]. For all mutations
found at codon 215, a much higher percentage were 215F or Y
among treated patients than among patients with TDR. T215Y
and T215F mutations have signiﬁcant ﬁtness costs in the
absence of ART, but these costs are reportedly lower for T215C,
D, and S [36]. Seeing higher-cost mutations in treated patients
implies that these mutations may revert in the absence of drug
pressure. Additionally, we found that diagnosis during primary
Figure 2. Patient clusters. For clarity, only the earliest sequence from each patient is shown. A and B, Clusters with 9 and 11 patients, respectively, with
the L90M mutation in the protease gene (red circle), of which 2 and 0 were treatment experienced (blue square), respectively. B, Two heterosexual males
(orange diamonds) are present. C, Transmission cluster including the T215F mutation in a drug-naive sequence (**), which is not present in 2 earlier infect-
ed sequences in the cluster (green triangles). Drug resistance mutations are shown at the tips. The cluster also contains 3 heterosexuals, 2 men (orange di-
amonds), and 1 woman (yellow diamond). Abbreviation: GRT, genotypic resistance test.
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infection was more common for surveillance patients with
ART-resistant virus. This could reﬂect reversion occurring
between transmission and viral sequencing; if more time passes
before a GRT is conducted, less TDR may be detected.
Despite this evidence for TDR reversion, our results indicate
that, overall, therapy-naive patients are the predominant
sources of TDR. Two patterns suggested that long transmission
chains of TDR occur in Switzerland. We found that a majority
(56/66 [84.8%]) of potential TDR sources are ART-naive pa-
tients. We also identiﬁed several large clusters of TDR contain-
ing mainly ART-naive patients. These results highlight that
although reversion occurs in patients not taking antiretrovirals,
it often does not occur quickly or completely enough to prevent
resistance mutations from being transmitted further. Particu-
larly, the example of L90M in the protease demonstrates that
resistance mutations can exhibit an apparently undiminished
spread even after the drugs selecting for them dramatically de-
creased in use. A similar cluster was found in [37]. This implies,
more generally, that even if the evolution of drug resistance mu-
tations during treatment were completely preventable, the spread
of TDR might continue. Several previous studies have also found
that ART-naive patients contribute to the transmission of drug-
resistant HIV-1 [11, 14, 38]. Thus, screening should be intensi-
ﬁed to detect HIV infections earlier, to allow for early treatment
as recommended in some recent treatment guidelines [39, 40].
Early treatment of patients with drug-resistant HIV would
rapidly reduce the circulation of resistant viruses in the ART-
naive population and interrupt this vicious cycle.
Although our study has a high representativeness of the sur-
veillance population, we do not have GRTs for the entire
epidemiologic network included in the study (patients not in-
cluded in the SHCS-DRDB, not diagnosed, or infected outside
the country), and can only assess patients in clusters in our
sample population. We also focused on subtype B HIV in MSM
in a resource-rich country. Finally, our methods also could not
always resolve the direction of infection. However, this poten-
tial limitation has no major effect on our results because we
found only 1 cluster in which infection dates of sources and
surveillance patients were ambiguous and directionality thus
was not clearly deﬁned. Although it is thus unclear to what
extent our results are generalizable to other risk groups, sub-
types, or countries, they indicate a high potential of HIV drug
resistance to circulate among treatment-naive patients. This
highlights the importance of limiting the acquisition of drug re-
sistance before it becomes established in untreated patients,
and of early test-and-treat strategies to prevent resistance trans-
mission from untreated patients.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online
(http://cid.oxfordjournals.org/). Supplementary materials consist of data
Figure 4. Sensitivity analysis. In the main analysis we used a bootstrap
criterion of 70% with a genetic distance of <1.5% to determine source–
recipient relationships, but here we considered the impact that varying
these criteria had on the number of recipients for whom a source could be
identiﬁed. Abbreviation: TDR, transmitted drug resistance.
Figure 3. There has been a strong decrease in use of saquinavir (red
dotted line) and nelﬁnavir (red dashed line), but not in the incidence of
90M mutations in newly diagnosed patients (black line). The conﬁdence
interval for the 90M mutation incidence (derived by bootstrapping) is
shown in blue shading. Due to small numbers, incidence data were pooled
every 2 years. The smaller conﬁdence intervals for the use of saquinavir
and nelﬁnavir are omitted for visual clarity. Abbreviations: GRT, genotypic
resistance test; NFV, nelﬁnavir; SHCS, Swiss HIV Cohort Study; SQV,
saquinavir.
292 • CID 2014:58 (15 January) • HIV/AIDS
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materials are not copyedited. The contents of all supplementary data are the
sole responsibility of the authors. Questions or messages regarding errors
should be addressed to the author.
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